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Introduction
Ischemic heart diseases represent one of the major causes of mor-
bidity and death, particularly in western societies. Two major cell
therapeutic strategies for heart repopulation after cardiac damage
have been proposed and are currently developed, based on the
regenerative potential of either cardiac and/or extra-cardiac stem
cells (CSCs). In the last years, the finding that the heart contains a
reservoir of resident stem and progenitor cells opened new per-
spectives in the biology of cardiac regeneration, suggesting to
explore experimental procedures aimed at in vitro expansion of
CSCs, for in vivo transplantation. CSCs are positive for various
stem/progenitor cell markers (Kit, Sca-1, Isl-1 and side population
– SP – properties), propagate in vitro and develop features of heart
cells after differentiation in vitro or in vivo [1–8]. Our own group
has described a method of isolation and expansion of mouse and
human heart adult stem cells (ASCs): these cells grow to form
contractile cardiospheres (CSs), which include stem/progenitor
cells of cardiac lineages and are able to improve cardiac function
when transplanted into infarcted heart. [1] The regenerative 
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Experimental data suggest that cell-based therapies may be useful for cardiac regeneration following ischaemic heart disease. Bone mar-
row (BM) cells have been reported to contribute to tissue repair after myocardial infarction (MI) by a variety of humoural and cellular
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tein under the control of Kit regulatory elements, into wild-type irradiated recipients. Following haematological reconstitution and MI,
CSCs were cultured from cardiac explants to generate ‘cardiospheres’, a microtissue normally originating in vitro from CSCs. These were
all green fluorescent (i.e. BM derived) and contained cells capable of initiating differentiation into cells expressing the cardiac marker
Nkx2.5. These findings indicate that, at least in conditions of local acute cardiac damage, BM cells can home into the heart and give rise
to cells that share properties of resident Kit CSCs.
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effectiveness of such CSs, derived from percutaneous endomy-
ocardial biopsy specimens, has been confirmed in more recent
studies [8, 9]. However, the most used cellular source for experi-
ments of cardiac repair and for clinical trials has been the bone
marrow (BM), an easily accessible tissue which harbours different
types of stem and progenitor cells, capable of contributing to the
regeneration of multiple tissues [10–19]. A critical question is
whether the endogenous CSC pool may be replenished by BM-
derived stem cells. Heart cells derive from two waves of multipo-
tent/bipotent embryonic stem progenitor cells [20–22] and mouse
chimera experiments rule out any major (greater than 5%) subse-
quent contribution to the adult CSCs population from ‘immigrant’
non-CSCs [23], under physiological conditions. On the other
hand, the presence of cardiac chimerism in patients receiving allo-
genic BM transplantation suggested that immigrant BM-derived
cells could generate at least some cardiac cells [24]. It remains
unclear whether these immigrant cells convert into myocytes
directly or via a CSC intermediate cell capable of self-replication
and long-term cardiac regeneration. If the latter is the case, excit-
ing biological and therapeutic possibilities may arise. We
addressed the question whether, following myocardial infarction
(MI), BM cells contribute to myocardic tissue repair by the gener-
ation of a cell population with the functional features of CSCs. We
combined two recent advancements made in our laboratories: (i )
first, the possibility to grow in vitro mouse CSCs, which exten-
sively proliferate, transiently express Kit and generate beating
CSs, capable of further cardiac differentiation [1, 8]; (ii ) second,
the generation of transgenic mouse line (Kit/GFP [green fluores-
cent protein]) that efficiently expresses GFP in a variety of stem
and progenitor Kit cells, including BM and CSCs, under the con-
trol of mouse Kit regulatory DNA regions [25–28]. In the present
work, we transplanted lethally irradiated mice with BM cells
expressing the Kit/GFP transgene. Following BM reconstitution
and induction of MI, cells from the explanted hearts were grown
in vitro, to generate CS which, on the basis of GFP expression,
might reveal a BM origin. Indeed, GFP CSs were generated,
which were capable of extensive proliferation. Furthermore, they
contained a proportion of cells that spontaneously expressed car-
diac markers and were able, upon transplantation, to engraft the
heart of secondary wild-type (wt) mice infarcted.
These results indicate that, following local tissue injury, a
BM-derived population of Kit cells with CSCs properties may be
generated in the heart. We suggest that these cells are potentially
capable of long-term regeneration and might contribute to 
cardiac repair.
Materials and methods
Mice
Kit/GFP and wild-type (BDF1) mice were kept according to institutional reg-
ulations. Kit/GFP transgenic mice (line 3) have been described [25].
Bone marrow transplantation and myocardial
infarction
BDF1 female recipient mice, 8–12 weeks old, were lethally irradiated 
(830 rads, x-ray source) and tail-vein injected with 107 Kit/GFP BM cells.
Controls were injected with cell-free medium. Engrafted animals were
analysed 4–6 months after transplantation. To test the haematopoietic stem
cell potential of CSs, we intravenously transplanted lethally irradiated female
recipients with 5  105 or 106 Kit/GFP suspended single cells derived
from CSs, together with 5  104, 105 or 2  105 wild-type BM cells as sup-
port. Transplanted animals were subjected to MI by left anterior descending
coronary artery (LAD) ligation [29] 4, 5, 6 and 9 months after transplanta-
tion; after further 2–3 weeks, they were killed and analysed as required.
Processing and isolation of cardiosphere 
forming cells
Murine tissue was derived from infarcted or non-infarcted hearts of
Kit/GFP BM transplanted mice and processed as described [1]. Upon
growth on poly-D-lysine-coated dishes, many cells remained adherent,
while others progressively gave rise, after several days, to CSs, which
detached from the dish, floating in the medium. CSs were individually 
collected and expanded as adherent monolayers as described [8]. When
required for further analysis, secondary CSs were again obtained by growing
them on poly-D-lysine coated dishes.
Immunohistochemistry and microscopy
CSs and cardiosphere-derived cells (CSDCs) were fixed in ethanol/methanol
(4C, 10 min.), washed twice with Ca/Mg free PBS and permeabilized
(0.1% Triton X-100 and 1% bovine serum albumin [BSA]).Non-specific
antibody-binding sites were blocked with 10% goat prior to incubation with
primary antibodies: anticardiac troponin (TnI, Sigma, Milan, Italy), anticar-
diac-specific transcription factor Nkx2.5, anti-smooth muscle actin or 
anti- galactosidase (-Gal), (Chemicon, Milan, Italy).
After washing in PBS containing 0.1% Triton X-100 and 1% BSA, cells
were incubated in Fitc-conjugated antimouse IgG or TRIC-conjugated anti-
rabbit secondary antibody (Chemicon).
Confocal microscopy was performed with a Leica TCS DMIRE 2 (LCS
lite software Leica, Leica, Milan, Italy), Vectashield mounting medium. No
significant fluorescent signal was detectable with any of the secondary
antibodies alone.
In vitro haematopoietic colony assays
Culture conditions for BM cells have been described [30]. For in vitro
colony assay of CSDCs, 105 wild-type CSDCs were plated in 35 mm dishes
containing 1 ml of the semisolid medium. Alternatively, single secondary
CSs were dissociated and plated in 96 multiwell plates (1 CS/well contain-
ing ~0.1 ml of the semisolid medium).
PCR and RT-PCR
DNA was prepared from BM and from single or pooled CSs by stan-
dard methods and the GFP transgene was detected by PCR using 
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5-ACATGAAGCAGCACGACTTC-3 and 5-TTGTGGCGGATCTTGAAGTT-3
primers, and its identity confirmed by sequencing.
Total RNA was isolated from CS expanded cells and from a pool of CSs
at days 3 and 8 after plating on poly-D-lysine, with the use of TriZol
(Invitrogen), according to the manufacturer’s instructions. Reverse tran-
scription was performed on 2 g starting RNA by M-MLV reverse tran-
scriptase (Invitrogen, Milan, Italy) in a 20 l reaction, and 2 l of cDNA
product were then subjected to PCR.
Conditions for the PCR on amplified cDNA template included enzyme
activation at 95C for 15 min., followed by 40 cycles (denaturation at 95C
for 15 sec., annealing at 58C for 60 sec. and extension at 72C 
for 60 sec.), with a final 4C step. Cardiac genes were detected using the 
following primers: Nkx2.5-FW 5-CAG TGG AGC TGG ACA AAG CC-3;
Nkx2.5-RV TAG CGA CGG TTC TGG AAC CA; Cardiac actin-FW TGA GAT GTC
TCT CTC TCT CTT AG; Cardiac actin-RV ACA ATG ACT GAT GAG AGA TG.
Results
BM-derived cells are able to generate 
cardiospheres in vitro
We previously [1, 8] identified in human and murine hearts a CSCs
population, based on the ability of cells derived from in vitro car-
diac explants to efficiently proliferate and to generate floating CSs.
CSs are a kind of microtissue, which spontaneously express cardiac
markers in a minority of cells and occasionally show synchronous
beating. They may undergo cardiac differentiation (in vitro and 
in vivo), and engraft the heart. The cell giving rise to the CS (CSCs)
is proposed to be a Kit precursor, based on immunofluorescence
studies with anti-Kit antibodies and analyses of CSCs from Kit/GFP
transgenic mice [1].
The Kit/GFP transgenic line expresses GFP from a construct
driven by mouse Kit gene promoter and enhancer elements, linked
to the GFP gene [25, 26] The transgene is appropriately expressed
in several Kit stem/ progenitor cell types, including primordial
germ cells, early haematopoietic progenitors and stem cells (HSC)
and CSCs [1, 25–28].
To investigate if BM-derived cells can give rise to CSCs, we
transplanted total BM from Kit/GFP transgenic mice into lethally
irradiated syngeneic non-transgenic mice (Fig. 1). After 5 months,
a subset of the recipient mice were subjected to MI, and after three
additional weeks, mice with or without MI were sacrificed. Full BM
reconstitution, as assessed by haematological parameters (Fig. S1),
was demonstrated.
In parallel, myocardial tissues were cultured as explants and
after 1–4 weeks an adherent layer of fibroblast-like cells was
formed and small, phase-bright cells migrated on top of it. These
phase-bright cells were plated under conditions supporting the
formation of CSs (Fig. 2). CS-forming cells were harvested at least
four times at 6- to 10-day intervals from the same explant. Once
formed, primary CSs (5–10/heart) were collected and amplified 
[1, 8], by growing them as adherent cells for 1 month, and subse-
quently transferred back onto poly-D-lysine-coated plates to gen-
erate large numbers of secondary CSs for analysis.
Efficient cell growth and CS formation was achieved in six of
nine mice with MI, but not in mice not subjected to MI. During cul-
ture in fibronectin, very few cells expressed GFP, as expected [1];
however, all CSs that developed in poly-D-lysine (whether primary
or secondary) contained the GFP transgene (as demonstrated by
PCR) and progressively expressed GFP, marking a relatively large
proportion of cells (Figs 2 and S2). At late stages of CS develop-
ment, smaller numbers of GFP cells persist, suggesting that the
kit/GFP is down-regulated (see below).
Cells from Kit/GFP BM-derived CS express 
cardiac markers
CSs grow by expansion of a central core of immature cells,
which initiate differentiation in the course of their displacement
to the periphery of the sphere; this results in the appearance of
a small number of cells positive for Nkx2.5, a transcription fac-
tor representing an early cardiac marker, and occasionally
Troponin I, a latter cytoplasmic marker [1]. A very low level of
in vitro differentiation of a type of Kit CSC was also reported
by Anversa’s group [6]. A representative pool of about 120 CSs,
derived from six different transplanted mice, were collected and
individually stained with antibodies against Nkx2.5 or Troponin
I to evaluate both antibody staining and GFP fluorescence.
Confocal analysis shows cells that express GFP together with
Nkx2.5 (Figs 3A, B and S2). The percentage of GFP cells co-
expressing Nkx2.5 is rather variable, ranging between 5% and
50% and depends on the developmental stage of the CSs.
Conversely, a very low level of GFP, if any, is stained by anti-TnI-
antibody (data not shown). This suggests that cells, which
occasionally commit to cardiomyocyte differentiation (i.e. are
Nkx2.5), progressively extinguish Kit/GFP expression, while
up-regulating cardiac-specific genes. Interestingly, when a
GFP CS is dissociated and the resulting cells are replated in
fibronectin, the kit/GFP gene is substantially down-regulated;
however, if the cells are again grown on polylisine, GFP expres-
sion is reactivated (Fig. 3C). This is in agreement with previous
findings by Messina et al. [1]. Thus, BM-derived cells present in
the CS may express cardiac markers.
CSs have no haematopoietic potential
We also investigated whether haematopoietic progenitors, which
express Kit, might be present within the population of GFP cells
of CSs. Firstly, we grew BM cells from wild-type untreated or
transplanted-MI mice in the culture conditions used for CS forma-
tion. BM cells from two untreated and five transplanted-MI mice
were plated in fibronectin-coated dishes and after 2 days trans-
ferred to poly-D-lysine-coated multiwell plates. The cultures,
scored over a period of 1 month did not show any CS-like clones,
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but rather exhibited the morphological characteristics of 
mesenchymal cells (Fig. S3). Second, we plated CS cells, from
either fibronectin- or poly-D-lysine-coated cultures, in clonogenic
assays used for evaluation of haematopoietic progenitors.
Cultures, scored at various time-points, did never reveal formation
of haematopoietic colonies (not shown).
Finally, we analysed CSs to verify whether they might harbour
haematopoietic stem cells, capable of long-term BM reconstitution.
© 2011 The Author
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Fig. 1 Schematic represen-
tation of the experimental
design.
Fig. 2 Kit/GFP CS and CS-
forming-cells. (A) Kit/GFP
CS-forming cells were col-
lected from the explant of
infarcted heart 13 days after
the beginning of the culture,
and plated onto poly-D-lysine
for 1 day to allow CS forma-
tion. Note the initial appear-
ance of slightly fluorescent
cells. (B) A CS at a more
advanced stage of develop-
ment shows transgenic
Kit/GFP expressing cells at
the centre of the sphere. (C)
PCR analysis of Kit/GFP in
genomic DNA extracted from
single CSs. 351–441 indicate
different transplanted-
infarcted mice; LD, size-
marker; Ca and Cb repre-
sent internal positive controls
(genomic DNA from 107 and
106 Kit/GFP BM cells); WT,
genomic DNA from 107 wild-
type BM cells; PCR-, negative control on PCR mix. Product of amplification from sample 438 was confirmed by in vitro automatic sequencing (not
shown).
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Pools of CSs from Kit/GFP transgenic newborn mice, were
injected into lethally irradiated recipients together with small num-
bers of wild-type BM cells as support. None of the reconstituted
mice had CS-derived BM cells (Fig. S4), not even those trans-
planted with 106 CS cells, as assessed by PCR. We conclude that
CSs do not seem to have haematopoietic potential.
Discussion
It was recently proposed that exogenous BM-derived cells can be
introduced, or mobilized, into the heart, to regenerate cardiomy-
ocytes and/or vascular endothelium, leading to functional heart
improvement [10–14, 24, 31]. The mechanism for the beneficial
effect of BM cells on the heart is controversial. Initial suggestions
that BM Kit cells may transdifferentiate into cardiomyocytes,
independently of cell fusion [10, 31–33], were rejected by others,
at least as far as haematopoietic cell types were considered [15,
16, 18, 34]. However, non-haematopoietic BM cells were reported
to generate cardiomyocytes or cells with immunophenotypic
properties of cardiac progenitors after homing to the heart [12,
35]; moreover, cardiomyocyte conversion of angioblastic lineages
has been proposed as being obtainable by direct contact of cells
with cardiomyocytes [36]. Finally, it was shown that relatively
large numbers of BM cells home to the heart after MI and con-
tribute to an improvement in cardiac function mainly through the
release of angiogenic cytokines [19].
Here we show that small numbers of Kit/GFP-labelled BM cells,
recruited to the heart following BM transplantation and cardiac
infarction, are able to extensively proliferate in vitro, participating
in the generation and growth of CSs. Cells from these CSs express
the early cardiac marker Nkx2.5 in vitro. These data show that,
under pathological conditions such as an infarction, BM-derived
cells may give rise, in the heart, to a progeny that shares at least
some of the properties of endogenous CSC.
BM-derived Kit/GFP cells form in vitro CSs
The rationale for our experimental strategy is that resident CSCs
are Kit [6, 28] and that Kit/GFP cells from the heart of Kit/GFP
transgenic participate in cardiac cell generation and CSs formation
in vitro [1]. Thus, if CS cells from mice transplanted with trans-
genic Kit/GFP marrow show GFP expression, they must derive
from the BM; as Kit is a marker expressed in CSCs, GFP expres-
sion from these cells may represent the activation of a CSC
© 2011 The Author
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Fig. 3 CS and CSDCs phenotypes.
Confocal analysis of a CS, derived
from the infarcted heart of a lethally
irradiated mouse transplanted with
marrow cells of Kit/GFP transgenic
mice (A) Merged image showing
co-expression in some cells
(arrows) of donor cell-derived GFP
(green) and Nkx2.5 (an immature
cardiac cell-specific transcription
factor) (red); nuclei are stained blue
by Hoechst dye. The figure is an
average of 13 z-axis confocal sec-
tions. Single channel fluorescence
intensity of some cells within the
sphere is represented by the plots,
depicting the fluorescence of cells
traced by the white line. Co-localiza-
tion is evident for the cells indicated
as cell 1 and 2 whereas the third
nucleus is expressing neither GFP
nor Nkx2.5. (B) Single cell derived
from CS dissociation (from a differ-
ent CS), demonstrating nuclear co-
localization of GFP and Nkx2.5. (C)
RT-PCR of GFP, Nkx2.5 and cardiac
actin from cells expanded on
fibronectin from a single clonogenic
CS, and later analysed as a mono-
layer on fibronectin (left) or as CSs
(on polylisine).
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 transcriptional program [1, 28]. In this view, BM cells from this
transgenic line have been previously used to study cell trafficking:
highly purified GFP stem/progenitor cells from BM were
recruited to muscle following local injury and participated in
regeneration [37].
In our experiments, all CSs that grew from the hearts of trans-
planted (and infarcted mice) showed GFP fluorescence and in all
CSs observed, a relatively large proportion of the cells were GFP
(Figs 2 and S2) indicating that endogenous CSCs were virtually
absent in the heart of these mice; if any endogenous CSC had still
been present, we should have seen at least some CS consisting
entirely or predominantly of unlabelled cells.
Consistent with this result, explants from Kit/GFP BM trans-
planted mice that had not undergone MI, did not give rise to any
CS. The lack of CS development from hearts of non-infarcted mice
is not unexpected, for several reasons: first, the number or activ-
ity of CS-forming cells greatly declines post-natally, particularly in
the mouse strain used for transplantation experiments (data not
shown), and CS culture was carried out in mice at a relatively
advanced age (greater than 8 months), due to the constraints of
the experimental protocol; second, injury is required in adult mice
to ‘activate’ stem/precursor cells, inducing them to regenerate car-
diomyocytes [38]; third, it is conceivable that the irradiation nec-
essary for BM transplantation may have damaged the endogenous
CSC population and/or their niche, either directly or through irra-
diation-dependent anaemia and white blood cell deficiency.
Infarction mobilizes and recruits into the heart a variety of BM
cells [39]. Thus, we interpret our results to signify that, in CSC-defi-
cient irradiated mice, following MI, the heart is repopulated, with
BM cells. Some of them develop into Kit/GFP cells resembling in
their growth-properties endogenous CS-forming cells. A proportion
of GFP cells within CS do indeed express, at low levels, Nkx2.5
(Figs 3 and S2). Whether these BM cells could represent a potential
source of endogenous CSCs will require further detailed examina-
tion of their functional properties. In this line, experiments are in
progress to evaluate whether CS-derived cells obtained in vitro as
described above are able to engraft damaged myocardium, generat-
ing new muscle fibres. Preliminary data suggest that cells from BM-
derived CSs may engraft and give rise to cardiomyocytes and vas-
cular cells in vivo (Fig. S5).
Biological and functional implications 
of BM-derived CSCs
We have shown that BM-derived cells can convert, upon migration
to the heart, into cells that, when placed in vitro, can extensively
replicate and give rise to precursors with CS-forming properties.
Importantly, these observations differ in many respects from pre-
vious results of other investigators. It was initially proposed that
direct implantation of BM cell populations into infarcted
myocardium, or their mobilization from the BM into the circulation
at the time of infarction, could lead to cardiomyocyte and/or
 vascular endothelium regeneration by transdifferentiation, inde-
pendently of cell fusion [31, 33].
Whether or not these experiments are accepted, our results
clearly differ from them, as we do not propose that BM cells
directly transdifferentiate into myocardial cells, but rather suggest
that they give rise to a ‘stem cell’ type that may persist in the heart,
and participate in regenerative repair after MI.
A further link was recently established between endogenous
cardiac repair, BM-derived cells and Kit function [19, 39]. Upon
MI, Kit cells from the BM are recruited to the heart, leading to
neovasculogenesis and to formation of repair tissue via paracrine
signalling pathways. These processes were strongly attenuated in
Kit-mutant mice, causing precipitous cardiac failure. Although
only a minority of the recruited cells persisted in the myocardium
a month after the infarction, these experiments did not rule out the
 possibility that these cells may contribute to the pool of CSCs, and
the authors concluded that their studies ‘raise the possibility that
the putative cardiac c-Kit stem cells are in actuality not from the
heart’ [19]. In agreement with this suggestion, our study provides
evidence of a cardiac population of BM-derived cells exhibiting
some properties of resident CSCs and potentially useful for car-
diac regeneration. Thus, the functional role of Kit cells that we
propose may be complementary to the non cell-autonomous func-
tion described by Fazel et al. [19]. Finally, a rare non-haematopoi-
etic cell type (mesenchymal stem cell, MSC) in BM was also found
to migrate to the heart upon infarction, and to give rise to a small
number of cardiomyocytes [12], thus suggesting the potential
usefulness of these stromal stem cells for cardiac cell therapy. In
addition, BM-derived cells were shown to be able to migrate to the
heart, generating cells with an immunophenotype corresponding
to that of endogenous CSC [35]. Our results are consistent with
these findings, and suggest that the reported [12] MSC to car-
diomyocyte transition might occur via a cell showing the self
renewing and differentiation features of CSCs.
A final issue concerns cell fusion, which was suggested to be
the underlying cause of many transdifferentiation events previously
reported [40, 41]. We cannot stringently rule out that cell fusion
may have occurred in our experiments, but we think it is unlikely.
The number of endogenous functional CSCs in the heart in the 
8-month-old transplanted mice used in our experiments is very
low, as indicated by our inability to grow any CSC from these hearts
in the absence of MI (and thus of recruitment of exogenous cells to
the heart), and a fusion event is therefore extremely improbable. It
remains possible that exogenous Kit/GFP cells have occasionally
fused to endogenous myocardial cells; however, this event would
explain only the appearance of labelled cardiac fibres, but not of
mononucleated, extensively dividing cells, as we report here.
The nature of the BM cell responsible for the generation of CS
in our experiments remains to be better clarified. It might be either
haematopoietic or more likely, mesenchymal. Our results, how-
ever, provide evidence that CSs do not contain haematopoietic
stem or progenitor cells as such: first, BM cells grown in vitro
under conditions appropriate for CS formation do not give rise 
to any CS-like aggregate; second, even large numbers of cells
derived from CSs are not capable of in vitro colony formation or
in vivo BM reconstitution, upon transplantation. Thus, BM-derived
cells that give rise to CSs are likely to be of a non-haematopoietic
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cell type. In agreement with this, previous work [16] showed that
haematopoietic-derived cells do not transform into skeletal or car-
diac muscle. The precise identification of the BM cell type respon-
sible for CS formation in this experimental protocol still requires
rigorous investigation, and might be addressed by fractionation of
Kit/GFP BM cells prior to transplantation.
In conclusion, we demonstrate generation of cells exhibiting
CS-forming properties from BM-derived cells in the heart of irra-
diated mice subjected to cardiac damage. This may have not only
induced the recruitment of cells to the heart, but also stimulated
the conversion of some cells to CS-forming cells. Our experiments
do not allow establishing whether irradiation-dependent cardiac
damage or infarction is strictly necessary. These observations,
however, provide the first evidence that cells with extensive prolif-
eration potential (i.e. CSC-like cells) can be generated in the heart
from exogenously derived cells, raising the possibility that these
extracardiac cells might, potentially, be directed to replenish the
CSC pool in damaged hearts.
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Supporting information
Additional Supporting Information may be found in the online ver-
sion of this article:
Fig. S1 Haematopoietic reconstitution of Kit/GFP bone marrow-
transplanted mice.
The haematopoietic reconstitution of mice transplanted with
Kit/GFP bone marrow was assessed after 4 months using clono-
genic assays: (A) Haematopoietic precursors in donor and trans-
planted mice, (B) Percentage of reconstitution in the transplanted
mice, as assessed by the percentage of fluorescent CFU-Mix
colonies, (C) Example of fluorescent CFU-Mix colony (left, bright
field; right, fluorescence).
Fig. S2 Kit/GFP and Nkx2.5 expression in different layers of a
 cardiosphere.
Confocal analysis of a CS, derived from the infarcted heart of a
lethally irradiated mouse transplanted with marrow cells of
Kit/GFP transgenic mice (A) Merged image showing co-expres-
sion in some cells (arrows) of donor cell-derived GFP (green) and
Nkx2.5 (an immature cardiac cell-specific transcription factor)
(red); nuclei are stained blue by Hoechst dye. The figure is an
average of 13 z-axis confocal sections. Single channel fluores-
cence in different layers of the sphere is represented by his-
tograms, depicting the fluorescence of each cell (B).
Fig. S3 In vitro bone marrow cells cultured in CS supporting
medium. Bone marrow cells were cultured following the culture pro-
tocol used to obtain cardiospheres from heart explants. No sphere-
like aggregates were obtained after culture in polylisine, while mes-
enchymal-like monolayers were observed (left, 100; right, 200).
Fig. S4 Analysis of CSC haematopoietic potential. (A) Schematic
representation of the experimental procedure adopted to test the
haematopoietic potential of CSC; (B) PCR on genomic DNA
extracted from 107 bone marrow cells of each transplanted mouse
4 months after receiving a transplant of cardiosphere cells from
the heart of Kit/GFP transgenic mice: none of the recipient animals
(labelled from 422 to 436) showed the presence of Kit/GFP con-
struct (C, positive control; wt, untransplanted wt mouse).
Fig. S5 Engraftment and Differentiation of CSDCs. Confocal
analyses of infarcted heart section of a wild-type mouse, 20 days
after injection of -galactosidase (-Gal)-lentivirally labelled
cells from GFP cardiospheres obtained from hearts of Kit/GFP
marrow-transplanted mice. (A) Low magnification picture of the
CSDCs (identified with a primary antibody against nuclear 
-galactosidase (red)) that are present in the transmural infarct,
with cells expressing myosin heavy chain (MHC, green) in the
regenerating area. (aI) higher magnification views of picture
shown in panel a: co-localization of -Gal CSDCs and viable
myocardium (arrows). (aII–aIV) Same picture showing the
nuclear -Gal expression, red (aIII), the corresponding Hoechst
labelling (arrows) (aII) and (aIV) a merged image of the three flu-
orescent channels (MHC, green).
(B) nuclear -Gal(green)-expressing CSDCs, double labelled for
smooth muscle actin (red), are shown within the vessels walls
(arrows) in the context of the infarcted area.
(bI–bIII) Single fluorescent channels view of cells indicated in
panel b: the -Gal-stained nuclei (bI, green) correspond to the
Hoechst-labelling (blue) in the same cells (bII). In bIII, smooth
muscle actin positive cells in the same field. bIV) merged image of
the three fluorescent channels.
(c-cI) Haematoxylin/eosin and -Gal (blue) hystochemical stain-
ing of criosections from one of the infarcted hearts, explanted 20
days after CSDCs injection: engraftment of the -Gal (blue)
stained CSDCs is shown. Blue-labelled nuclei are present within
the haematoxylin and eosin stained area.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to
the corresponding author for the article.
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